Whereas, Rates of marijuana use among the US population has increased in the past decade; and

Whereas, Marijuana is a complex botanical with many different compounds with potential pharmacological activity; and

Whereas, There is some high quality evidence for efficacy of some marijuana compounds for treatment of disease or alleviation of symptoms; and

Whereas, There are structural impediments to high quality research due to marijuana being classified as a Schedule I substance by the Food and Drug Administration; and

Whereas, There is accumulating evidence about harms associated with marijuana use in regards to accidents, impaired driving, psychosis, depression, and suicide; and

Whereas, There is little long term data on the efficacy and potential harms associated with medical or non-medical use; and

Whereas, Practicing clinicians could provide better recommendations for medicinal use with high quality research; and

Whereas, There is emerging data from the states which have legalized marijuana use; and

Whereas, Review and analysis of the emerging data would be helpful to state medical societies as they provide advice to their governmental representatives and regulators as they formulate policies toward marijuana; therefore be it

RESOLVED, That our American Medical Association review pertinent data from those states that have legalized marijuana. (Directive to Take Action)

Fiscal Note: Not yet determined

Received: 04/25/19